SymBio Announces Results Presented at ASCO 2012 Evaluating Clinical Benefits ... MarketWatch (press release) TOKYO, Jun 04, 2012 (MARKETWIRE via COMTEX) -- SymBio Pharmaceuticals Limited (jasdaq:4582) announced today that results from a multicenter, Phase II study assessing the efficacy and safety of bendamustine in combination with rituximab (BR) in patients ... |
